← Back to Clinical Trials
Recruiting NCT00114647

NCT00114647 Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00114647
Status Recruiting
Phase
Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Condition Healthy Volunteers
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 1984-01-09
Primary Completion

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 1984-01-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will collect blood plasma and white blood cells from individuals using a procedure called apheresis. Apheresis is a method of collecting larger quantities of certain blood components that can safely be collected through a simple blood draw. The blood components will be used in laboratory research studies. Patients 18 years of age and older who are currently enrolled in a NIH clinical research protocol may participate in this study. Relatives of patients and normal healthy volunteers will also be enrolled. Individuals will undergo one of the following two apheresis procedures: * Automated pheresis Blood is drawn through a needle placed in an arm vein and circulated through a cell separator machine. The plasma (liquid part of the blood) and white cells are extracted, and the red cells are re-infused into the donor through the same needle or a needle in the other arm. An anticoagulant (medication to prevent blood from clotting) is usually added to the blood while in the machine to prevent it from clotting during processing. * Manual pheresis One unit (1 pint) of blood is drawn through a needle placed in an arm vein, similar to donating a pint of whole blood. The red blood cells, with or without plasma, are separated from the rest of the blood and returned to the donor through the same needle. Manual pheresis will be done only when a person s estimated total blood volume or red cell count is too low to safely permit removal of blood through a pheresis machine. An adult small in size or markedly anemic, for example, may fall into this category. Some of the blood collected through apheresis may be stored for future studies of HIV disease and immune function and for HLA testing, a genetic test of markers of the immune system. Some of the blood may be used to screen for different types of viral liver infections, such as hepatitis A, B, C, D, E, F, or G. ...

Eligibility Criteria

* INCLUSION CRITERIA: 18 years of age or older Adequate venous access Blood pressure less than or equal to 180/100; pulse rate 50-100, unless a lower pulse rate is considered normal for the volunteer (e.g. a conditioned athlete) Adequate blood counts if undergoing apheresis (HIV positive volunteers and volunteers with vasculitis or other inflammatory diseases: hemoglobin greater than or equal to 9.0 g/dL, HCT greater than or equal to 28%, platelets greater than or equal to 50,000; HIV negative volunteers: hemoglobin greater than or equal to 12.5 g/dL, HCT greater than or equal to 38%, platelets greater than or equal to 150,000) Willing and able to provide written informed consent, comply with study requirements and procedures, and comply with clinic policies (including stored samples, hepatitis screening, and genetic testing including HLA testing) EXCLUSION CRITERIA: Pregnant and/or breast-feeding women Currently abusing alcohol or other drugs Any medical condition for which the PI feels apheresis or other sample collection procedures might be contraindicated

Contact & Investigator

Central Contact

Holly A Baus, R.N.

✉ holly.baus@nih.gov

📞 (301) 761-6800

Principal Investigator

Susan L Moir, Ph.D.

PRINCIPAL INVESTIGATOR

National Institute of Allergy and Infectious Diseases (NIAID)

Frequently Asked Questions

Who can join the NCT00114647 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Healthy Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00114647 currently recruiting?

Yes, NCT00114647 is actively recruiting participants. Contact the research team at holly.baus@nih.gov for enrollment information.

Where is the NCT00114647 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT00114647 clinical trial?

NCT00114647 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Susan L Moir, Ph.D. at National Institute of Allergy and Infectious Diseases (NIAID). The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology